FR2491926A1 - Raubasine (ajmalicine or delta-yohimbine) anti-anoxic derivs. - used for treat cerebral vascular damage, cerebral sclerosis, cranial trauma disorders and depressive states - Google Patents

Raubasine (ajmalicine or delta-yohimbine) anti-anoxic derivs. - used for treat cerebral vascular damage, cerebral sclerosis, cranial trauma disorders and depressive states Download PDF

Info

Publication number
FR2491926A1
FR2491926A1 FR8021643A FR8021643A FR2491926A1 FR 2491926 A1 FR2491926 A1 FR 2491926A1 FR 8021643 A FR8021643 A FR 8021643A FR 8021643 A FR8021643 A FR 8021643A FR 2491926 A1 FR2491926 A1 FR 2491926A1
Authority
FR
France
Prior art keywords
radical
sep
alkoxycarbonyl
acid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8021643A
Other languages
French (fr)
Other versions
FR2491926B1 (en
Inventor
Bernard Mompon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthelabo SA
Original Assignee
Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo SA filed Critical Synthelabo SA
Priority to FR8021643A priority Critical patent/FR2491926A1/en
Publication of FR2491926A1 publication Critical patent/FR2491926A1/en
Application granted granted Critical
Publication of FR2491926B1 publication Critical patent/FR2491926B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Raubasine (ajmalicine or delta-yohimbine) derivs. of formula (I) and their acid addn. salts are new. Cpds. are 1-R1-16,17-didehydro-19 -alpha-methyl-16 -R2-CO-oxayohimbane derivs. R1 is H, 1-4C alkoxycarbonyl, phenoxycarbonyl (where the phenyl ring is opt. substd.by halo or nitro), 1-4C acyl or 1-4C-alkoxycarbonyl-1-4C-alkyl and R2 is O-Me (where Me is an alkali or alkaline earth metal), opt. branched 2-4C alkoxy, 3-6C-cycloalkyl-1-4C-alkoxy, 3-6C-cycloalkoxy, amino, mono- or di-(1-4C alkyl)amino or 3-6C cycloalkyl-amino. (I) are anti-anoxics used to treat vigilance troubles e.g. cerebral vascular damage, cerebral sclerosis in the elderly, cranial trauma disorders and depressive states. They may be administered orally or parenterally in daily doses of 10-200 mg. I.p. LD50 in mice varies from 300-1000 mg/kg and in hypobaric anoxia tests on mice, the mean active dose which increases survival time by 100% was 10-60 mg/kg i.p..

Description

La présente invention a pour objet des dérivés de raubasine, leur préparation et leur application en thérapeutique.The present invention relates to raubasin derivatives, their preparation and their therapeutic application.

Dans le brevet n 79 25353 ont été décrits des dérivés de l'acide oxayohimbane-carboxylique portant un groupe R sur l'azote du noyau indolique. i
La Demanderesse a poursuivi ses recherches dans ce domaine et préparé plusieurs nouveaux dérivés de la raubasine.In Patent No. 79 25353 there have been described derivatives of oxayohimbanecarboxylic acid carrying a group R on the nitrogen of the indole nucleus. i
The Applicant has continued his research in this area and prepared several new derivatives of raubasine.

Les composés répondent à la formule (I)

Figure img00010001

dans laquelle
R1 est un atome d'hydrogène,
un radical (C1-4)-alcoxycarbonyle,
un radical phénoxycarbonyle dont le phényle peut porter
un atome d'halogène ou un groupe nitro,
un radical (C1-4)-acyle,
un radical (C1-4)-alcoxycarbonyle-(C1-4)-alkyle,
R2 est un radical OMe (Me = métal alcalin ou alcalinoterreux),
un radical (C2 4)-alcoxy droit ou ramifié,
un radical (C3-6) -cycloalkyl- (C14) -alcoxy,
un radical (C3-6)-cycloalcoxy,
le radical amino,
un radical (C1-4)-alkylamino,
un radical di (Cl 4)-alkyl-amino,
un radical (C3-6)-cycloalkyl-amino,
Les sels d'addition des composés (I) aux acides pharmaceutiquement acceptables font partie de l'invention.The compounds correspond to formula (I)
Figure img00010001

in which
R1 is a hydrogen atom,
a (C1-4) -alkoxycarbonyl radical,
a phenoxycarbonyl radical whose phenyl may carry
a halogen atom or a nitro group,
a (C1-4) -acyl radical,
a (C1-4) -alkoxycarbonyl- (C1-4) -alkyl radical,
R2 is an OMe radical (Me = alkali metal or alkaline earth metal),
a radical (C2 4) -alkoxy straight or branched,
a (C 3-6) -cycloalkyl- (C 14) -alkoxy radical,
a (C 3-6) -cycloalkoxy radical,
the amino radical,
a (C1-4) -alkylamino radical,
a di (Cl 4) -alkyl-amino radical,
a (C3-6) -cycloalkyl-amino radical,
The addition salts of compounds (I) with pharmaceutically acceptable acids form part of the invention.

Les composés préférés de l'invention sont ceux dans lesquels
R1 est un radical alcoxycarbonyle ou un radical alcoxycarbonylalkyle.The preferred compounds of the invention are those in which
R 1 is an alkoxycarbonyl radical or an alkoxycarbonylalkyl radical.

La matière de départ est la raubasine (ou ajmalicine) (R1=H,
R2=OCHE).The starting material is raubasin (or ajmalicin) (R1 = H,
R2 = OCHE).

On peut également utiliser comme matière de départ une base quaternaire pseudo-aromatique,la serpentine et réduire cette dernière par hydrogénationcatalytique ou par un borohydrure de métal alcalin en un composé tétrahydrogéné.A pseudoaromatic quaternary base, serpentine, can also be used as starting material and the latter can be reduced by catalytic hydrogenation or by an alkali metal borohydride to a tetrahydrogenated compound.

Selon l'invention on peut preparer les composés de la manière suivante
On prépare l'acide I (R1=H, R2=OH) à partir de la raubasine (R1=H, R2=CH3O) par saponification. On peut obtenir les esters (I) selon des méthodes classiques, notamment soit par estéri fiction directe de l'acide, (par reaction entre le chlorure d'acide et l'alcool R2H ou un de ses sels alcalins) soit par transestérification de la raubasine.According to the invention, the compounds can be prepared in the following manner
Acid I (R1 = H, R2 = OH) is prepared from raubasin (R1 = H, R2 = CH3O) by saponification. The esters (I) can be obtained by conventional methods, in particular either by direct esterification of the acid, (by reaction between the acid chloride and the R2H alcohol or an alkaline salt thereof) or by transesterification of the raubasine.

On obtient les amides (I) à partir de l'acide (I) R1=H, R2=OH) ou de l'un de ses dérivés fonctionnels par amidification classique.The amides (I) are obtained from the acid (I) R1 = H, R2 = OH) or from one of its functional derivatives by conventional amidification.

Les composés (I) portant un radical Rlf H sont obtenus à partir des composés (I) dans lesquels R1 est H par reaction du composé avec un halogénure d'alcoxycarbonyle ou d'alcoxycarbonylalkyle, c'est à dire que l'on forme l'anion de la raubasine, par exemple par solubilisation de la base dans du diméthylformamide et action de l'hydrure de sodium, puis on ajoute alors le composé
R1X (X= Cl ou Br). Compounds (I) carrying a radical Rlf H are obtained from compounds (I) in which R1 is H by reacting the compound with an alkoxycarbonyl or alkoxycarbonylalkyl halide, ie forming the anion of raubasin, for example by solubilization of the base in dimethylformamide and action of sodium hydride, and then the compound is added
R1X (X = Cl or Br).

La réaction est effectuée à une température de O à 200C. The reaction is carried out at a temperature of 0 to 200C.

Les exemples suivants. illustrent l'invention.The following examples. illustrate the invention.

Les analyses et les spectres IR et RMN confirment la structure des composés.Analyzes and IR and NMR spectra confirm the structure of the compounds.

EXEMPLE 1 Ethylamide de l'acide méthoxycarbonyl-l didéhydro
16,17 méthyl-l9 α oxayohimbane-carboxylique.

Figure img00030001
EXAMPLE 1 Ethylamide of methoxycarbonyl-1 didehydro acid
16.17 methyl-19 α oxayohimbane-carboxylic acid.
Figure img00030001

<tb><Tb>

[R1 <SEP> - <SEP> COOCH3, <SEP> R2 <SEP> - <SEP> @@C2H5]
<tb> 1. Acide oxayohimbane carboxylique didéhydro-16,17 méthyl-19 &alpha;. [R1 <SEP> - <SEP> COOCH3, <SEP> R2 <SEP> - <SEP> @@ C2H5]
<tb> 1. Oxayohimbane carboxylic acid didehydro-16,17 methyl-19 &alpha;

On fait réagir 60 g (0,170 mole) de raubasine, en solution dans 2 1 de méthanol et 1 1 d'eau, avec 31. g de soude (0,785 mole).60 g (0.170 mol) of raubasin, dissolved in 2 l of methanol and 1 l of water, are reacted with 31 g of sodium hydroxide (0.785 mol).

On porte le mélange réactionnel pendant 19 heures à la température du reflux.The reaction mixture is heated at reflux temperature for 19 hours.

Après évaporation du méthanol, on acidifie le mélange avec de l'acide chlorhydrique. On filtre le produit précipité et on le lave à l'eau. Après chromatographie sur gel de silice on obtient l'acide que l'on fait recristalliser dans un mélange
CH2Cl2/CH3OH (1/1).

Figure img00030002
After evaporation of the methanol, the mixture is acidified with hydrochloric acid. The precipitated product is filtered and washed with water. After chromatography on silica gel, the acid is obtained which is recrystallized from a mixture
CH2Cl2 / CH3OH (1/1).
Figure img00030002

<tb><Tb>

F <SEP> = <SEP> 205 C <SEP> [&alpha;]# <SEP> <SEP> = <SEP> -41,5 <SEP> (c=0,6
<tb> pyridine 2. Ethylamide de l'acide didéhydro-16,11 méthyl-19 &alpha; &alpha; oxayohim-
bane carboxylique.F <SEP> = <SEP> 205 C <SEP>[&alpha;]#<SEP><SEP> = <SEP> -41.5 <SEP> (c = 0.6
<tb> pyridine 2. Ethylamide of 16,11-didehydro-16-methyl-α-acid; &alpha; oxayohim-
carboxylic acid.

On prépare d'abord le chlorure de l'acide par réaction de ce dernier (25 g) en solution dans du chloroforme (1 1) en présenc de pyridine (9 cm ) avec du chlorure d'oxalye (23 cm ) en solution dans du chloroforme sec (25 cm ). Le réaction est effectuée à froid. On porte le mélange réactionnel pendant 2 heures à la température du reflux.The acid chloride is first prepared by reaction of the latter (25 g) in solution in chloroform (1 1) in the presence of pyridine (9 cm) with oxaloyl chloride (23 cm) in solution in dry chloroform (25 cm). The reaction is carried out cold. The reaction mixture is heated for 2 hours at reflux temperature.

On ajoute 7 g d'êthylamine. 7 g of ethylamine are added.

On laisse revenir le mélange réactionnel à la température ambiante et on l'agite pendant 1 heure.The reaction mixture was allowed to warm to room temperature and stirred for 1 hour.

On ajoute alors de l'eau, décante et extrait au chloroforme. Water is then added, decanted and extracted with chloroform.

On lave la phase organique avec de l'eau puis la sèche sur
MgSO4. On évapore à siccité et obtient un solide que l'on fait recristalliser dans un mélange CH3OH/CH3Cl2.

Figure img00040001
The organic phase is washed with water and then dried over
MgSO4. It is evaporated to dryness and a solid is obtained which is recrystallized from a CH3OH / CH3Cl2 mixture.
Figure img00040001

<tb><Tb>

F <SEP> = <SEP> 267-8 C <SEP> (dec) <SEP> [&alpha;]# <SEP> = <SEP> -28,7 <SEP> <SEP> (C=1,65 <SEP> CH3OH)
<tb> 3. Ethylamide de l'acide méthoxycarbonyl-l didéhydro-16,17
méthyl-19&alpha; oxayohimbane-carboxylique.F <SEP> = <SEP> 267-8 C <SEP> (dec) <SEP>[&alpha;]#<SEP> = <SEP> -28.7 <SEP><SEP> (C = 1.65 <SEP> CH3OH)
<tb> 3. Ethylamide of methoxycarbonyl-1-didehydro-16,17
methyl-19 &alpha; oxayohimbane-carboxylic acid.

On fait réagir 2 g du produit obtenu orécédemment sous 2, sous forme de chlorhydrate, en solution dans 40 cm3 de diméthylformamide, en présence de 1 g (0,019 mole) d'hydrure de sodium à 50% avec 1,5 cm3 (0,019 mole) de chloroformiate de méthyle sous argon.2 g of the product obtained previously under 2, in hydrochloride form, are dissolved in 40 cm 3 of dimethylformamide in the presence of 1 g (0.019 mol) of 50% sodium hydride with 1.5 cm 3 (0.019 mol). ) of methyl chloroformate under argon.

Après avoir agité, on ajoute de l'eau, extrait avec de l'oxyde de diethyle, lave à l'eau glacée plusieurs fois et sèche sur
MgSO4. Après évaporation à sec, le produit cristallise. Après recristallisation dans un mélange CH2Cl2/(C2H5)2O, il fond à 168-90C.

Figure img00040002
After stirring, add water, extract with diethyl ether, wash with ice water several times and dry on
MgSO4. After evaporation to dryness, the product crystallizes. After recrystallization from CH2Cl2 / (C2H5) 2O, it melts at 168-90C.
Figure img00040002

<tb><Tb>

[&alpha;]# <SEP> <SEP> = <SEP> - <SEP> 192,7 <SEP> (c=0,7, <SEP> CH3OH)
<tb>
TABLEAU

Figure img00050001
[&alpha;]#<SEP><SEP> = <SEP> - <SEP> 192.7 <SEP> (c = 0.7, <SEP> CH3OH)
<Tb>
BOARD
Figure img00050001

<tb> Composé <SEP> R1 <SEP> R2 <SEP> F <SEP> ( C) <SEP> [&alpha;]#
<tb> <SEP> 1 <SEP> H <SEP> OC4H9 <SEP> HCl-300 <SEP> -9,5 <SEP> (c=0,8
<tb> <SEP> CH3OH)
<tb> <SEP> 2 <SEP> H <SEP> NHC2H5 <SEP> HCl-267-8 <SEP> -28,7 <SEP> (c=1,7
<tb> <SEP> CH3OH)
<tb> <SEP> 3 <SEP> COOCH3 <SEP> NHC2H5 <SEP> Base-168-9 <SEP> -192,7 <SEP> (c=0,7
<tb> <SEP> CH3OH). <SEP>
<tb> <tb> Compound <SEP> R1 <SEP> R2 <SEP> F <SEP> (C) <SEP>[&alpha;]#
<tb><SEP> 1 <SEP> H <SEP> OC4H9 <SEP> HCl-300 <SEP> -9.5 <SEP> (c = 0.8
<tb><SEP> CH3OH)
<tb><SEP> 2 <SEP> H <SEP> NHC2H5 <SEP> HCl-267-8 <SEP> -28.7 <SEP> (c = 1.7
<tb><SEP> CH3OH)
<tb><SEP> 3 <SEP> COOCH3 <SEP> NHC2H5 <SEP> Base-168-9 <SEP> -192.7 <SEP> (c = 0.7
<tb><SEP> CH3OH). <September>
<Tb>

Les composés de l'invention ont été soumis à des essais pharmacologiques.The compounds of the invention have been subjected to pharmacological tests.

La toxicité des composés a été déterminée par voie intrapéritonéale sur des souris.The toxicity of the compounds was determined intraperitoneally in mice.

La DL 50 varie de 300 à 1000 mg/kg. The LD 50 varies from 300 to 1000 mg / kg.

Les composés ont été soumis au test de l'anoxie hypobare.The compounds were subjected to the hypobaric anoxia test.

Des souris de souche CDî sont maintenues dans une atmosphère appauvrie en oxygène, par réalisation d'un vide partiel (190 mm de mercure correspondant à 5,25% d'oxygène). CD1 strain mice are maintained in an oxygen-depleted atmosphere by performing a partial vacuum (190 mm Hg corresponding to 5.25% oxygen).

Le temps de survie des animaux est noté. Ce temps est augmenté par les agents capables de favoriser l'oxygénation tissulaire et en particulier cérébrale. Les composés étudiés sont administrés, à plusieurs doses, par voie intrapéritonéale, 10 minutes avant l'essai. Les pourcentages d'augmentation du temps de survie par rapport aux valeurs obtenues chez les animaux témoins sont calculés. La dose active moyenne (DAM), dose qui augmente le temps de survie de 100% est déterminée graphiquement.The survival time of the animals is noted. This time is increased by the agents capable of promoting tissue oxygenation and in particular cerebral oxygenation. The compounds studied are administered, in several doses, intraperitoneally, 10 minutes before the test. The percentages of increase of the survival time compared to the values obtained in the control animals are calculated. The mean active dose (AMD), which increases the survival time by 100%, is determined graphically.

La DAM des composés de l'invention varie de 10 à 60 mg/kg par voie i.p.The DAM of the compounds of the invention ranges from 10 to 60 mg / kg i.p.

L'étude pharmacologique des composés de l'invention montre qu'ils sont actifs dans l'épreuve d'anoxie hypobare chez la souris tout en n'étant que peu toxiques.The pharmacological study of the compounds of the invention shows that they are active in the test of hypobaric anoxia in mice while being only slightly toxic.

Les composés de l'invention, possédant une activité antiano xique, peuvent être utilisés en thérapeutique pour le traitement des troubles de la vigilance, en particulier pour lutter contre les troubles du comportement imputables à des dommages vasculaires cérébraux et à la sclérose cérébrale en gériatrie, ainsi que pour le traitement des absences dues à des traumatismes craniens, et le traitement des états dépressifs.The compounds of the invention, possessing an antianoic activity, can be used in therapy for the treatment of vigilance disorders, in particular for combating behavioral disorders attributable to cerebrovascular damage and cerebral sclerosis in geriatrics, as well as for the treatment of absences due to cranial trauma, and the treatment of depressive states.

L'invention comprend par conséquent, toutes compositions pharmaceutiques renfermant les composés et/ou leurs sels comme principes actifs, en association avec tous excipients appropriés à leur administration, en particulier par voie orale ou parentérale.The invention therefore includes any pharmaceutical compositions containing the compounds and / or their salts as active ingredients, in combination with any excipients suitable for their administration, in particular orally or parenterally.

Les voies d'administration peuvent Btre les voies orale et parentérale
La posologie quotidienne peut aller de 10 à 200 mg. The routes of administration may be the oral and parenteral routes
The daily dosage can range from 10 to 200 mg.

Claims (4)

Revendications claims un radical (C36)-cycloalkyl-amino, ainsi que leurs sels d'addition aux acides pharmaceutiquement acceptables.  a (C36) -cycloalkylamino radical, as well as their pharmaceutically acceptable acid addition salts. un radical di (cl~4)-alkyl-amino,  a di (cl-4) -alkyl-amino radical, un radical (C1-4)-alkylamino, a (C1-4) -alkylamino radical, le radical amino, the amino radical, un radical (C36)- cycloalcoxy, a radical (C36) - cycloalkoxy, un radical (C3-6)-cycloalkyl-(C1-4)-alcoxy, a (C3-6) -cycloalkyl- (C1-4) -alkoxy radical, un radical (C2-4)-alcoxy droit ou ramifie, a (C2-4) -alkoxy radical straight or branched, R2 est un radical OMe (Me = métal alcalin ou alcalinoterreux) r R2 is an OMe radical (Me = alkali metal or alkaline earth metal) r un radical (C1~4)-alcoxycarbonyI-(C1~4)-alkyle,  a radical (C1-4) -alkoxycarbonyl- (C1-4) alkyl, un radical (C1-4)-acyle, a (C1-4) -acyl radical, un atome d'halogène ou un groupe nitro, a halogen atom or a nitro group, un radical phénoxycarbonyle dont le phényle peut porter a phenoxycarbonyl radical whose phenyl may carry un radical (C1-4)-alcoxycarbonyle, a (C1-4) -alkoxycarbonyl radical, R1 est un atome d'hydrogène,R1 is a hydrogen atom, dans laquelle in which
Figure img00080001
Figure img00080001
 .1. Dérivés de la raubasine répondant à la formule '(I).1. Derivatives of raubasine corresponding to the formula '(I) 2. Dérivés selon la revendication 1, dans lesquels R1 est un radical alcoxycarbonyle ou alcoxycarbonyl-alkyle.2. Derivatives according to claim 1, wherein R1 is an alkoxycarbonyl or alkoxycarbonyl-alkyl radical. 3. Procedé de préparation des composés selon la revendication 1, procédé caractérisé en ce que l'on prépare l'acide I (R1=H, 3. Process for the preparation of the compounds according to claim 1, characterized in that the acid I (R1 = H, R2=OH) à partir de la raubasine (R1=H, R2=CH30) par saponification, puis on prepare les esters (I) selon des méthodes classiques, notamment soit par estérification directe de l'acide, (par réaction entre le chlorure d'acide et l'alcool R2H ou un de ses sels alcalins) soit par transestérification de la raubasine ; on prépare les amides (I) à partir de l'acide (I) R1=H, R2 = OH) from raubasin (R1 = H, R2 = CH3O) by saponification, and then the esters (I) are prepared according to conventional methods, in particular either by direct esterification of the acid, (by reaction between the chloride acid and the R2H alcohol or an alkali metal salt thereof) by transesterification of raubasin; the amides (I) are prepared from (I) acid R1 = H, R2=OH) ou de l'un quelconque de ses dérivés fonctionnels par amidification classique et on prépare les composés (I) portant un radical R1 # H à partir des composes (I) dans lesquels R1 est H par réaction du composé avec un halogènure R1X : on forme l'anion de la raubasine, par exemple par solubilisation de la base dans du diméthylformamide et action de l'hydrure de sodium, puis on ajoute alors le composé R1X (X=C1 ou Br). R2 = OH) or any of its functional derivatives by conventional amidification and compounds (I) bearing a radical R1 # H are prepared from the compounds (I) in which R1 is H by reaction of the compound with a halogenide R1X: The anion of raubasin is formed, for example by solubilization of the base in dimethylformamide and action of sodium hydride, and then the compound R1X (X = C1 or Br) is added. 4. Médicament caractérisé en ce qu'il contient un composé selon 1'une quelconque des revendications 1 et 2. 4. A medicament characterized in that it contains a compound according to any one of claims 1 and 2.
FR8021643A 1980-10-10 1980-10-10 Raubasine (ajmalicine or delta-yohimbine) anti-anoxic derivs. - used for treat cerebral vascular damage, cerebral sclerosis, cranial trauma disorders and depressive states Granted FR2491926A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR8021643A FR2491926A1 (en) 1980-10-10 1980-10-10 Raubasine (ajmalicine or delta-yohimbine) anti-anoxic derivs. - used for treat cerebral vascular damage, cerebral sclerosis, cranial trauma disorders and depressive states

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8021643A FR2491926A1 (en) 1980-10-10 1980-10-10 Raubasine (ajmalicine or delta-yohimbine) anti-anoxic derivs. - used for treat cerebral vascular damage, cerebral sclerosis, cranial trauma disorders and depressive states

Publications (2)

Publication Number Publication Date
FR2491926A1 true FR2491926A1 (en) 1982-04-16
FR2491926B1 FR2491926B1 (en) 1983-08-19

Family

ID=9246725

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8021643A Granted FR2491926A1 (en) 1980-10-10 1980-10-10 Raubasine (ajmalicine or delta-yohimbine) anti-anoxic derivs. - used for treat cerebral vascular damage, cerebral sclerosis, cranial trauma disorders and depressive states

Country Status (1)

Country Link
FR (1) FR2491926A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281607A (en) * 1992-10-08 1994-01-25 New York University Method of using Alpha 2-Antagonists for the Treatment of Neurodegenerative Diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2442664A1 (en) * 1978-12-01 1980-06-27 Bbc Brown Boveri & Cie DUST SEPARATOR FOR ELIMINATING DUST, EVEN FINE, PRESENT IN FLOWS OF GASEOUS FLUIDS
FR2450825A1 (en) * 1979-03-09 1980-10-03 Synthelabo BENZODIAZEPINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATION

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2442664A1 (en) * 1978-12-01 1980-06-27 Bbc Brown Boveri & Cie DUST SEPARATOR FOR ELIMINATING DUST, EVEN FINE, PRESENT IN FLOWS OF GASEOUS FLUIDS
FR2450825A1 (en) * 1979-03-09 1980-10-03 Synthelabo BENZODIAZEPINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATION

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281607A (en) * 1992-10-08 1994-01-25 New York University Method of using Alpha 2-Antagonists for the Treatment of Neurodegenerative Diseases

Also Published As

Publication number Publication date
FR2491926B1 (en) 1983-08-19

Similar Documents

Publication Publication Date Title
FR2534257A1 (en) NOVEL 6-AMINO 7-HYDROXY 4,5,6,7-TETRAHYDRO-IMIDAZO / 4,5,1-JK / / 1 / BENZAZEPIN-2 (1H) -ONE DERIVATIVES, THEIR SALTS, APPLICATION AS MEDICAMENTS , COMPOSITIONS COMPRISING THEM AND AN INTERMEDIARY
EP0307303A1 (en) 1-[(2-Pyrimidinyl)-aminoalkyl] piperidines, their preparation and their use in therapy
WO1997003987A1 (en) Novel galanthamine derivatives, preparation method therefor, use thereof as drugs, and pharmaceutical compositions containing such derivatives
CH645642A5 (en) D-6-N-PROPYLERGOLINS DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
EP0087378B1 (en) Oxime-ethers of alkylamino alcohols as medicaments, compounds and process for their preparation
FR2584713A1 (en) NOVEL CARBOXAMIDE INDOLE DERIVATIVES, THEIR SALTS, PROCESS AND PREPARATION INTERMEDIATES, MEDICAMENT APPLICATION AND COMPOSITIONS COMPRISING SAME
EP0209770A1 (en) Eicosatriynoic esters and amides and their use in pharmacy and cosmetics
EP1720849B1 (en) Pyranone derivatives useful for treating cancer
FR2551063A1 (en) New 2,5-dimethylpyrroles, process for preparing them and their therapeutic use
FR2491926A1 (en) Raubasine (ajmalicine or delta-yohimbine) anti-anoxic derivs. - used for treat cerebral vascular damage, cerebral sclerosis, cranial trauma disorders and depressive states
EP0043752B1 (en) Pyranoindole derivative and process for its preparation
EP0130882B1 (en) Bicyclo(3.2.1)octane carboxylic-acid derivatives, processes for their preparation and their therapeutical use
EP0082040B1 (en) 3,7a-diazacyclohepta(j,k)fluorene derivatives, their preparation and therapeutical use
FR2758560A1 (en) NEW DERIVATIVES OF AMINOPHENYLBORONIC ACIDS, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2465733A1 (en) NOVEL IMIDAZOLYLETHOXYMETHYLIC DERIVATIVES OF 1,3-DIOXOLOQUINOLINES USEFUL AS ANTIBACTERIAL AND ANTIFUNGAL DRUGS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS AND PHARMACEUTICAL FORMS CONTAINING THEM
CA1060020A (en) Process for the preparation of new dibenzo/b,c/ thiepine derivatives and salts thereof
FR2723372A1 (en) NOVEL STREPTOGRAMIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP1131293A1 (en) 1-aminoethylquinoline derivatives for treating urinary incontinence
BE864450R (en) ANTHOCYANIDINE-BASED PHARMACEUTICAL COMPOSITIONS, THEIR PREPARATION AND THEIR USE
EP1242381A2 (en) 2-phenyl-quinoline derivatives, preparation method and therapeutic use thereof
LU82833A1 (en) OXAYOHIMBANE-CARBOXYLIC ACID DERIVATIVES
FR2581996A1 (en) NOVEL 6-SUBSTITUTED 6H-DIBENZO (B, D) THIOPYRANES DERIVATIVES USEFULLY IMMUNOMODULATORS AND ANTIVIRALS AND THEIR PREPARATION
EP0647221A1 (en) 1-aryl(4-o-alkoxyphenyl 1-piperazinyl)-2, -3 or -4 alkanols, process for their preparation and use thereof in the preparation of drugs
EP0179076A1 (en) Sulphureous hydantoin derivatives and pharmaceutical compositions containing them.
FR2556592A1 (en) Pharmaceutical compositions containing camphormethylidenecinnamic acid derivatives

Legal Events

Date Code Title Description
ST Notification of lapse